A public consultation shows that the current EU system of medicines safety monitoring (pharmacovigilance) needs rationalisation and strengthening. There are unclear roles and responsibilities, complex reporting rules implemented differently by different Member States, a lack of robust safety studies and complex decision-making at EU-level.
